165 related articles for article (PubMed ID: 20933117)
1. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system.
Maruo T; Ohara N; Yoshida S; Nakabayashi K; Sasaki H; Xu Q; Chen W; Yamada H
Contraception; 2010 Nov; 82(5):435-41. PubMed ID: 20933117
[TBL] [Abstract][Full Text] [Related]
2. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas.
Maruo T; Ohara N; Matsuo H; Xu Q; Chen W; Sitruk-Ware R; Johansson ED
Contraception; 2007 Jun; 75(6 Suppl):S99-103. PubMed ID: 17531625
[TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells.
Xu Q; Ohara N; Liu J; Amano M; Sitruk-Ware R; Yoshida S; Maruo T
Mol Hum Reprod; 2008 Mar; 14(3):181-91. PubMed ID: 18216291
[TBL] [Abstract][Full Text] [Related]
4. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer.
Morikawa A; Ohara N; Xu Q; Nakabayashi K; DeManno DA; Chwalisz K; Yoshida S; Maruo T
Hum Reprod; 2008 Apr; 23(4):944-51. PubMed ID: 18281245
[TBL] [Abstract][Full Text] [Related]
5. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells.
Xu Q; Ohara N; Chen W; Liu J; Sasaki H; Morikawa A; Sitruk-Ware R; Johansson ED; Maruo T
Hum Reprod; 2006 Sep; 21(9):2408-16. PubMed ID: 16720624
[TBL] [Abstract][Full Text] [Related]
7. Progestin-releasing intrauterine systems and leiomyoma.
Kaunitz AM
Contraception; 2007 Jun; 75(6 Suppl):S130-3. PubMed ID: 17531604
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells.
Ohara N; Morikawa A; Chen W; Wang J; DeManno DA; Chwalisz K; Maruo T
Reprod Sci; 2007 Dec; 14(8 Suppl):20-7. PubMed ID: 18089606
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma.
Shimomura Y; Matsuo H; Samoto T; Maruo T
J Clin Endocrinol Metab; 1998 Jun; 83(6):2192-8. PubMed ID: 9626159
[TBL] [Abstract][Full Text] [Related]
10. Effects of progesterone on uterine leiomyoma growth and apoptosis.
Maruo T; Matsuo H; Samoto T; Shimomura Y; Kurachi O; Gao Z; Wang Y; Spitz IM; Johansson E
Steroids; 2000; 65(10-11):585-92. PubMed ID: 11108863
[TBL] [Abstract][Full Text] [Related]
11. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.
Wang J; Ohara N; Wang Z; Chen W; Morikawa A; Sasaki H; DeManno DA; Chwalisz K; Maruo T
Hum Reprod; 2006 Jul; 21(7):1869-77. PubMed ID: 16613890
[TBL] [Abstract][Full Text] [Related]
12. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes.
Murat Naki M; Tekcan C; Ozcan N; Cebi M
Fertil Steril; 2010 Jun; 94(1):371-4. PubMed ID: 19896649
[TBL] [Abstract][Full Text] [Related]
13. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient.
Fong YF; Singh K
Contraception; 1999 Jul; 60(1):51-3. PubMed ID: 10549453
[TBL] [Abstract][Full Text] [Related]
14. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
Magalhães J; Aldrighi JM; de Lima GR
Contraception; 2007 Mar; 75(3):193-8. PubMed ID: 17303488
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells.
Wang J; Ohara N; Takekida S; Xu Q; Maruo T
Hum Reprod; 2005 Jun; 20(6):1456-65. PubMed ID: 15760954
[TBL] [Abstract][Full Text] [Related]
16. Effects of progesterone on growth factor expression in human uterine leiomyoma.
Maruo T; Matsuo H; Shimomura Y; Kurachi O; Gao Z; Nakago S; Yamada T; Chen W; Wang J
Steroids; 2003 Nov; 68(10-13):817-24. PubMed ID: 14667973
[TBL] [Abstract][Full Text] [Related]
17. Sex steroidal regulation of uterine leiomyoma growth and apoptosis.
Maruo T; Ohara N; Wang J; Matsuo H
Hum Reprod Update; 2004; 10(3):207-20. PubMed ID: 15140868
[TBL] [Abstract][Full Text] [Related]
18. Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus.
Tasci Y; Caglar GS; Kayikcioglu F; Cengiz H; Yagci B; Gunes M
Arch Gynecol Obstet; 2009 Jul; 280(1):39-42. PubMed ID: 19066923
[TBL] [Abstract][Full Text] [Related]
19. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
[TBL] [Abstract][Full Text] [Related]
20. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.
Varma R; Sinha D; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):9-28. PubMed ID: 16325993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
